ArticleNature communications2017
Inhibition of Y1 receptor signaling improves islet transplant outcome.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Targeting hypothalamic SIK3 to promote weight loss and improve glycemic control in mice.Nature communications · 2026Article
- The role of PYY in improving insulin resistance.Frontiers in endocrinology · 2026Review
- Article
- Identification of SEC16B as a novel regulator of glucose homeostasis.Diabetologia · 2025Article
- EDIL3 alleviates Mannan-induced psoriatic arthritis by slowing the intracellular glycolysis process in mononuclear-derived dendritic cells.Inflammation · 2025Article
- Regulating islet stress responses through CD47 activation.Diabetologia · 2025Article
- MTCH2 Suppresses Thermogenesis by Regulating Autophagy in Adipose Tissue.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis.Science advances · 2025Article
- CREB1-driven CXCR4Nature communications · 2023Article
- Deficiency of neuropeptide Y attenuates neointima formation after vascular injury in mice.BMC cardiovascular disorders · 2023Article
- Article
- miR-320a induces pancreatic β cells dysfunction in diabetes by inhibiting MafF.Molecular therapy. Nucleic acids · 2021Article
- Peripheral-specific Y1 receptor antagonism increases thermogenesis and protects against diet-induced obesity.Nature communications · 2021Article
- The Utility of Exosomes in Diagnosis and Therapy of Diabetes Mellitus and Associated Complications.Frontiers in endocrinology · 2021Review
- Free fatty acid receptor 3 differentially contributes to β-cell compensation under high-fat diet and streptozotocin stress.American journal of physiology. Regulatory, integrative and comparative physiology · 2020Article
- Inhibition of Y1 Receptor Promotes Osteogenesis in Bone Marrow Stromal CellsFrontiers in endocrinology · 2020Article
- Y1 receptor deficiency in β-cells leads to increased adiposity and impaired glucose metabolism.Scientific reports · 2018Article
- Article
- Defining G protein-coupled receptor peptide ligand expressomes and signalomes in human and mouse islets.Cellular and molecular life sciences : CMLS · 2018Article
- [Neuropeptide Y Y1 receptor antagonist PD160170 promotes osteogenic differentiation of rat bone marrow mesenchymal stem cells in vitro and femoral defect repair in rats].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Failure to secrete sufficient quantities of insulin is a pathological feature of type-1 and type-2 diabetes, and also reduces the success of islet cell transplantation. Here we demonstrate that Y1 receptor signaling inhibits insulin release in β-cells, and show that this can be pharmacologically exploited to boost insulin secretion. Transplanting islets with Y1 receptor deficiency accelerates the normalization of hyperglycemia in chemically induced diabetic recipient mice, which can also be achieved by short-term pharmacological blockade of Y1 receptors in transplanted mouse and human islets. Furthermore, treatment of non-obese diabetic mice with a Y1 receptor antagonist delays the onset of diabetes. Mechanistically, Y1 receptor signaling inhibits the production of cAMP in islets, which via CREB mediated pathways results in the down-regulation of several key enzymes in glycolysis and ATP production. Thus, manipulating Y1 receptor signaling in β-cells offers a unique therapeutic opportunity for correcting insulin deficiency as it occurs in the pathological state of type-1 diabetes as well as during islet transplantation.Islet transplantation is considered one of the potential treatments for T1DM but limited islet survival and their impaired function pose limitations to this approach. Here Loh et al. show that the Y1 receptor is expressed in β- cells and inhibition of its signalling, both genetic and pharmacological, improves mouse and human islet function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.